 Carlos Roncal
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uric Acid | 14 | 2019 | 148 | 1.140 |
Why?
| | Fructose | 13 | 2018 | 100 | 1.050 |
Why?
| | Kidney Diseases | 9 | 2019 | 350 | 0.840 |
Why?
| | Hyperuricemia | 8 | 2019 | 43 | 0.650 |
Why?
| | Metabolic Syndrome | 7 | 2018 | 321 | 0.590 |
Why?
| | Allopurinol | 4 | 2019 | 53 | 0.470 |
Why?
| | Diabetic Nephropathies | 6 | 2019 | 234 | 0.420 |
Why?
| | Kidney | 11 | 2019 | 1188 | 0.410 |
Why?
| | Nephritis, Interstitial | 2 | 2007 | 7 | 0.360 |
Why?
| | Captopril | 1 | 2009 | 10 | 0.340 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 15 | 2019 | 2218 | 0.330 |
Why?
| | Uromodulin | 2 | 2019 | 21 | 0.320 |
Why?
| | Rats | 18 | 2019 | 4958 | 0.310 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 179 | 0.300 |
Why?
| | Arteriolosclerosis | 1 | 2007 | 1 | 0.290 |
Why?
| | Lead | 1 | 2007 | 43 | 0.280 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2019 | 3252 | 0.250 |
Why?
| | Cisplatin | 1 | 2007 | 262 | 0.250 |
Why?
| | Vascular Stiffness | 2 | 2019 | 407 | 0.230 |
Why?
| | Glucose | 5 | 2018 | 897 | 0.220 |
Why?
| | Glomerular Filtration Rate | 5 | 2019 | 604 | 0.220 |
Why?
| | Hypokalemia | 3 | 2008 | 24 | 0.220 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 638 | 0.220 |
Why?
| | Albuminuria | 3 | 2019 | 164 | 0.210 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 847 | 0.200 |
Why?
| | Dietary Sucrose | 3 | 2010 | 45 | 0.180 |
Why?
| | Chemokine CCL2 | 4 | 2009 | 105 | 0.180 |
Why?
| | Creatinine | 6 | 2018 | 425 | 0.170 |
Why?
| | Kidney Tubules | 4 | 2008 | 107 | 0.170 |
Why?
| | Glycocalyx | 1 | 2019 | 18 | 0.170 |
Why?
| | Animals | 26 | 2019 | 31708 | 0.170 |
Why?
| | Glycopeptides | 1 | 2019 | 43 | 0.160 |
Why?
| | Dehydration | 2 | 2016 | 40 | 0.160 |
Why?
| | Heat-Shock Response | 1 | 2018 | 46 | 0.150 |
Why?
| | Kidney Calculi | 1 | 2018 | 30 | 0.150 |
Why?
| | Sweetening Agents | 2 | 2009 | 37 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 40 | 0.150 |
Why?
| | Dietary Carbohydrates | 2 | 2009 | 138 | 0.150 |
Why?
| | Sugars | 1 | 2018 | 29 | 0.150 |
Why?
| | Hydrochlorothiazide | 2 | 2007 | 8 | 0.150 |
Why?
| | Oxidative Stress | 4 | 2019 | 1076 | 0.140 |
Why?
| | Diuretics | 2 | 2007 | 66 | 0.140 |
Why?
| | Proteinuria | 5 | 2008 | 77 | 0.140 |
Why?
| | Hypertension, Renal | 2 | 2007 | 12 | 0.140 |
Why?
| | Survival | 1 | 2016 | 37 | 0.130 |
Why?
| | Male | 23 | 2019 | 55606 | 0.130 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 1879 | 0.130 |
Why?
| | Water Supply | 1 | 2016 | 70 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2016 | 98 | 0.120 |
Why?
| | Heat Stress Disorders | 1 | 2015 | 40 | 0.120 |
Why?
| | Farmers | 1 | 2015 | 42 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 245 | 0.120 |
Why?
| | Climate Change | 1 | 2016 | 120 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2008 | 498 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2018 | 460 | 0.120 |
Why?
| | Macrophages | 4 | 2010 | 1263 | 0.110 |
Why?
| | Blood Pressure | 6 | 2009 | 1538 | 0.110 |
Why?
| | Inflammation | 3 | 2008 | 2480 | 0.100 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1629 | 0.100 |
Why?
| | Liver | 2 | 2018 | 1637 | 0.100 |
Why?
| | Body Weight | 4 | 2009 | 869 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 923 | 0.100 |
Why?
| | Kidney Tubules, Proximal | 2 | 2010 | 113 | 0.100 |
Why?
| | Hypertension | 4 | 2008 | 1056 | 0.100 |
Why?
| | Drug Synergism | 2 | 2009 | 316 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2009 | 154 | 0.090 |
Why?
| | Disease Models, Animal | 6 | 2009 | 3535 | 0.090 |
Why?
| | Insulin Resistance | 5 | 2009 | 1072 | 0.090 |
Why?
| | Urate Oxidase | 2 | 2008 | 9 | 0.090 |
Why?
| | Capillaries | 2 | 2007 | 91 | 0.090 |
Why?
| | Animal Feed | 1 | 2009 | 49 | 0.080 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 71 | 0.080 |
Why?
| | Angiostatins | 1 | 2008 | 3 | 0.080 |
Why?
| | Cells, Cultured | 6 | 2019 | 3886 | 0.080 |
Why?
| | Weight Gain | 2 | 2008 | 453 | 0.080 |
Why?
| | Biomarkers | 4 | 2019 | 3408 | 0.080 |
Why?
| | Kidney Glomerulus | 1 | 2008 | 100 | 0.070 |
Why?
| | Chronic Disease | 3 | 2008 | 1578 | 0.070 |
Why?
| | Fatty Liver | 1 | 2009 | 211 | 0.070 |
Why?
| | Leptin | 1 | 2008 | 210 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 951 | 0.070 |
Why?
| | Dietary Fats | 1 | 2008 | 287 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 1842 | 0.070 |
Why?
| | Renal Circulation | 1 | 2006 | 53 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2008 | 137 | 0.070 |
Why?
| | Inflammation Mediators | 2 | 2008 | 477 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 281 | 0.060 |
Why?
| | Young Adult | 5 | 2019 | 10471 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 750 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2009 | 2096 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 511 | 0.060 |
Why?
| | Nitric Oxide | 5 | 2008 | 823 | 0.060 |
Why?
| | Gout Suppressants | 2 | 2019 | 20 | 0.060 |
Why?
| | Risk Factors | 4 | 2019 | 8632 | 0.060 |
Why?
| | Fructokinases | 2 | 2018 | 29 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 797 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 123 | 0.060 |
Why?
| | Chemokines | 1 | 2005 | 216 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2009 | 731 | 0.060 |
Why?
| | Humans | 18 | 2019 | 114699 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 299 | 0.050 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 489 | 0.050 |
Why?
| | Organ Size | 3 | 2010 | 436 | 0.050 |
Why?
| | Adolescent | 5 | 2019 | 17853 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2008 | 687 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2007 | 2553 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2018 | 368 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2187 | 0.050 |
Why?
| | Aorta | 2 | 2019 | 386 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3003 | 0.040 |
Why?
| | Blotting, Western | 3 | 2008 | 1147 | 0.040 |
Why?
| | Fibrosis | 3 | 2008 | 453 | 0.040 |
Why?
| | Blood Urea Nitrogen | 2 | 2009 | 51 | 0.040 |
Why?
| | Calcium Oxalate | 1 | 2018 | 5 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 141 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 119 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 35 | 0.040 |
Why?
| | Pulse Wave Analysis | 1 | 2019 | 207 | 0.040 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 7 | 0.040 |
Why?
| | Carbonated Beverages | 1 | 2018 | 15 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 274 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 173 | 0.040 |
Why?
| | Female | 6 | 2019 | 59520 | 0.040 |
Why?
| | Beverages | 1 | 2018 | 60 | 0.040 |
Why?
| | Lipogenesis | 1 | 2018 | 56 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 442 | 0.040 |
Why?
| | Potassium | 2 | 2008 | 128 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 531 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 244 | 0.030 |
Why?
| | Sodium | 2 | 2007 | 183 | 0.030 |
Why?
| | Adult | 4 | 2019 | 30553 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 728 | 0.030 |
Why?
| | Cystatin C | 1 | 2015 | 62 | 0.030 |
Why?
| | El Salvador | 1 | 2015 | 5 | 0.030 |
Why?
| | Metformin | 1 | 2019 | 276 | 0.030 |
Why?
| | Models, Biological | 2 | 2015 | 1621 | 0.030 |
Why?
| | Eating | 1 | 2018 | 344 | 0.030 |
Why?
| | Child | 3 | 2019 | 18420 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 444 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 923 | 0.030 |
Why?
| | Saccharum | 1 | 2015 | 59 | 0.030 |
Why?
| | Mice, Inbred C57BL | 3 | 2009 | 4694 | 0.030 |
Why?
| | Insulin | 3 | 2008 | 2080 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 532 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1373 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 808 | 0.030 |
Why?
| | Phenotype | 1 | 2019 | 2797 | 0.020 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 501 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1796 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2008 | 2570 | 0.020 |
Why?
| | Glucose Transporter Type 5 | 1 | 2010 | 1 | 0.020 |
Why?
| | Glucose Transporter Type 2 | 1 | 2010 | 10 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 1828 | 0.020 |
Why?
| | Disease Progression | 2 | 2007 | 2380 | 0.020 |
Why?
| | Hyperplasia | 1 | 2010 | 163 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 46 | 0.020 |
Why?
| | Nephritis | 1 | 2009 | 20 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6116 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 7 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2894 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 17 | 0.020 |
Why?
| | Starvation | 1 | 2008 | 21 | 0.020 |
Why?
| | Gout | 1 | 2008 | 36 | 0.020 |
Why?
| | Adenoviridae | 1 | 2008 | 184 | 0.020 |
Why?
| | Potassium, Dietary | 1 | 2007 | 10 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 1727 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 110 | 0.020 |
Why?
| | Hypertrophy | 1 | 2008 | 109 | 0.020 |
Why?
| | Aldosterone | 1 | 2007 | 42 | 0.020 |
Why?
| | Actins | 1 | 2010 | 381 | 0.020 |
Why?
| | Hypothalamus | 1 | 2008 | 147 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 415 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2008 | 184 | 0.020 |
Why?
| | Urine | 1 | 2007 | 54 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2007 | 34 | 0.020 |
Why?
| | Mice | 3 | 2009 | 14871 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 467 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 26738 | 0.020 |
Why?
| | Magnesium | 1 | 2007 | 145 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 371 | 0.020 |
Why?
| | Atrophy | 1 | 2007 | 152 | 0.020 |
Why?
| | Fasting | 1 | 2008 | 241 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 427 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2006 | 23 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 335 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 173 | 0.020 |
Why?
| | Arterioles | 1 | 2006 | 39 | 0.020 |
Why?
| | Sodium Chloride, Dietary | 1 | 2006 | 30 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 430 | 0.020 |
Why?
| | Angiotensin II | 1 | 2006 | 87 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2006 | 113 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4410 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 993 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9088 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2005 | 140 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 838 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2005 | 182 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2005 | 120 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 2005 | 257 | 0.010 |
Why?
| | Antioxidants | 1 | 2008 | 530 | 0.010 |
Why?
| | Body Composition | 1 | 2008 | 590 | 0.010 |
Why?
| | Vasodilation | 1 | 2007 | 419 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2008 | 430 | 0.010 |
Why?
| | NF-kappa B | 1 | 2008 | 641 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1140 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 292 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 743 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2637 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1016 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 920 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2540 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1693 | 0.010 |
Why?
| | Aged | 1 | 2018 | 19074 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 959 | 0.010 |
Why?
| | RNA | 1 | 2005 | 809 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1473 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 1841 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2320 | 0.010 |
Why?
|
|
Roncal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|